PMV Pharmaceuticals is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies that target p53 mutations. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome”. Normal, or wildtype, p53 has the ability to eliminate cancer cells, however, mutant p53 proteins can be misfolded and lose their tumor suppressing function. These p53 mutations are found in approximately half of all human cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. PMV has leveraged more than four decades of research experience, developing unique insights into p53, to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their tumor suppressing function.
Data Provided by Refinitiv. Minimum 15 minutes delayed.